Consensus on molecular imaging and theranostics in neuroendocrine neoplasms

V Ambrosini, J Kunikowska, E Baudin, L Bodei… - European journal of …, 2021 - Elsevier
Nuclear medicine plays an increasingly important role in the management neuroendocrine
neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission …

Theranostics in nuclear medicine: emerging and re-emerging integrated imaging and therapies in the era of precision oncology

JF Gomes Marin, RF Nunes, AM Coutinho… - Radiographics, 2020 - pubs.rsna.org
Theranostics refers to the pairing of diagnostic biomarkers with therapeutic agents that share
a specific target in diseased cells or tissues. Nuclear medicine, particularly with regard to …

The North American neuroendocrine tumor society consensus guidelines for surveillance and medical management of pancreatic neuroendocrine tumors

TR Halfdanarson, JR Strosberg, L Tang, AM Bellizzi… - Pancreas, 2020 - journals.lww.com
This article is the result of the North American Neuroendocrine Tumor Society consensus
conference on the medical management of pancreatic neuroendocrine tumors from July 19 …

Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms

J Hofland, G Kaltsas, WW de Herder - Endocrine Reviews, 2020 - academic.oup.com
Neuroendocrine neoplasms constitute a diverse group of tumors that derive from the
sensory and secretory neuroendocrine cells and predominantly arise within the pulmonary …

NANETS/SNMMI consensus statement on patient selection and appropriate use of 177Lu-DOTATATE peptide receptor radionuclide therapy

TA Hope, L Bodei, JA Chan, G El-Haddad… - Journal of Nuclear …, 2020 - Soc Nuclear Med
MATERIALS AND METHODS Systematic Review To inform the development of these
guidelines, a systematic review of evidence was performed. We followed the Preferred …

PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy

L Bodei, MS Kidd, A Singh, WA Van Der Zwan… - European journal of …, 2018 - Springer
Background Peptide receptor radionuclide therapy (PRRT) utilizes somatostatin receptor
(SSR) overexpression on neuroendocrine tumors (NET) to deliver targeted radiotherapy …

New PET radiotracers for the imaging of neuroendocrine neoplasms

E Fortunati, G Argalia, L Zanoni, S Fanti… - … Treatment Options in …, 2022 - Springer
Opinion statement Neuroendocrine neoplasms (NEN) are a heterogeneous group of
tumours derived from cells of neuroendocrine origin and can potentially arise everywhere in …

Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy

L Bodei, H Schöder, RP Baum, K Herrmann… - The lancet …, 2020 - thelancet.com
Peptide receptor radionuclide therapy (PRRT) is a type of radiotherapy that targets peptide
receptors and is typically used for neuroendocrine tumours (NETs). Some of the key …

Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies

L Lee, T Ito, RT Jensen - Expert review of anticancer therapy, 2018 - Taylor & Francis
Introduction: Recently, there have been a number of advances in imaging pancreatic
neuroendocrine tumors (panNETs), as well as other neuroendocrine tumors (NETs), which …

Clinical Utility of 18F-FDG PET in Neuroendocrine Tumors Prior to Peptide Receptor Radionuclide Therapy: A Systematic Review and Meta-Analysis

E Alevroudis, ME Spei, SN Chatziioannou, M Tsoli… - Cancers, 2021 - mdpi.com
Simple Summary Functional imaging with 18F-fluorodeoxyglucose positron emission
tomography (18F-FDG PET) has evolved into a major clinical tool in cancer diagnosis and …